Annexon, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Annexon, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($206.69M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($138.20M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($134.24M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($141.95M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($130.32M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($63.41M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($37.18M) | Mar 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($216.41M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($154.07M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($143.72M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($145.60M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($130.71M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($63.47M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($32.52M) | Mar 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.70M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $119.45M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $113.76M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $112.50M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $100.07M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $49.27M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $24.52M | Mar 25, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($186.36M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($118.01M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($121.14M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($116.31M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($106.11M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($53.09M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($28.36M) | Mar 25, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $15.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $193.0K | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $6.53M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.65M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $464.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $267.0K | Mar 25, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $277.57M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $350.07M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $297.67M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $285.10M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $287.04M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $355.95M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $49.90M | Mar 25, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.92M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $56.97M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $47.12M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $53.90M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $55.13M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $11.67M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $6.37M | Mar 25, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $211.65M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $293.11M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $250.56M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $231.19M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $231.91M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $344.28M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($100.45M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($64.20M) | Mar 25, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($917.39M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($710.70M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($572.50M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($438.26M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($296.32M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($165.99M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($102.58M) | Mar 25, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.05M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $49.50M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $225.11M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $140.02M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $74.84M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $268.57M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $43.93M | Mar 25, 2021 |
| FY2020 | Dec 31, 2018 | $44.18M | Mar 25, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 6, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 6, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 149.36M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 109.38M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 78.37M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 47.72M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 38.56M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 38.16M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 433,749 | Mar 25, 2021 |